\u003c/p>\u003cp>智通財經APP獲悉,據報道,由于投資者對制藥商表現出濃厚興趣,傳奇生物(LEGN.US)正考慮在美國以外進行第二上市。報道引述知情人士稱,可能上市地點包括香港、新加坡和倫敦。尤其是在香港上市的情況下,第二上市可能有助于提升傳奇生物的估值。\u003c/p>\u003cp>報道指出,傳奇生物仍在進行考慮中,可能決定不進行第二上市。傳奇生物的代表不予置評。\u003c/p>\u003cp>傳奇生物成立于2014年,2020年于美國納斯達克上市。其主營腫瘤治療領域CAR-T細胞免疫療法,旗艦產品西達基奧侖賽已獲美國FDA批準上市。\u003c/p>","type":"text"}],"currentPage":0,"pageSize":1},"editorName":"葛瑤","editorCode":"PF216","faceUrl":"http://ishare.ifeng.com/mediaShare/home/8516/media","vestAccountDetail":{},"subscribe":{"type":"vampire","cateSource":"","isShowSign":0,"parentid":"0","parentname":"財經","cateid":"8516","catename":"智通財經APP","logo":"https://d.ifengimg.com/q100/img1.ugc.ifeng.com/newugc/20210201/13/wemedia/511f851ce203c0a061e2169b8968ae85aa8a7344_size41_w476_h476.jpg","description":"每天推送最具價值的港股、美股、A股投資資訊!","api":"http://api.3g.ifeng.com/api_wemedia_list?cid=8516","show_link":0,"share_url":"https://share.iclient.ifeng.com/share_zmt_home?tag=home&cid=8516","eAccountId":8516,"status":1,"honorName":"","honorImg":"","honorImg_night":"","forbidFollow":0,"forbidJump":0,"fhtId":"70303323","view":1,"sourceFrom":"","declare":"","originalName":"","redirectTab":"article","authorUrl":"https://ishare.ifeng.com/mediaShare/home/8516/media","newsTime":"2025-09-08 10:07:18","lastArticleAddress":"來自北京"},"filterMediaList":[{"name":"鳳凰網財經","id":"607286"},{"name":"國際財聞匯","id":"1609082"},{"name":"銀行財眼","id":"1444240"},{"name":"公司研究院","id":"1612328"},{"name":"IPO觀察哨","id":"1601888"},{"name":"風暴眼","id":"1601889"},{"name":"出海研究局","id":"1613468"},{"name":"封面","id":"540061"},{"name":"前行者","id":"1580509"},{"name":"凰家反騙局","id":"1596037"},{"name":"康主編","id":"1535116"},{"name":"啟陽路4號","id":"1021158"},{"name":"財經連環話","id":"7518"}]},"keywords":"生物,傳奇,納斯達克,腫瘤,財經,新加坡","safeLevel":0,"isCloseAlgRec":false,"interact":{"isCloseShare":false,"isCloseLike":false,"isOpenCandle":false,"isOpenpray":false,"isCloseFhhCopyright":false},"hasCopyRight":true,"sourceReason":"","__nd__":"ne883dbn.ifeng.com","__cd__":"c01049em.ifeng.com"};
var adKeys = ["adHead","adBody","topAd","logoAd","topicAd","contentAd","articleBottomAd","infoAd","hardAd","serviceAd","contentBottomAd","commentAd","commentBottomAd","articleAd","videoAd","asideAd1","asideAd2","asideAd3","asideAd4","asideAd5","asideAd6","bottomAd","floatAd1","floatAd2"];
var __apiReport = (Math.random() > 0.99);
var __apiReportMaxCount = 50;
for (var i = 0,len = adKeys.length; i 智通財經APP獲悉,據報道,由于投資者對制藥商表現出濃厚興趣,傳奇生物(LEGN.US)正考慮在美國以外進行第二上市。報道引述知情人士稱,可能上市地點包括香港、新加坡和倫敦。尤其是在香港上市的情況下,第二上市可能有助于提升傳奇生物的估值。 報道指出,傳奇生物仍在進行考慮中,可能決定不進行第二上市。傳奇生物的代表不予置評。 傳奇生物成立于2014年,2020年于美國納斯達克上市。其主營腫瘤治療領域CAR-T細胞免疫療法,旗艦產品西達基奧侖賽已獲美國FDA批準上市。 “特別聲明:以上作品內容(包括在內的視頻、圖片或音頻)為鳳凰網旗下自媒體平臺“大風號”用戶上傳并發布,本平臺僅提供信息存儲空間服務。 Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”
新股消息|傳傳奇生物(LEGN.US)擬在美國以外進行第二上市 香港為考慮地點之一


獨家搶先看